Biotoxtech Co., Ltd. (KOSDAQ:086040)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,275.00
-30.00 (-1.30%)
At close: Sep 18, 2026

Biotoxtech Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
52,47647,01741,34132,63137,29232,717
Other Revenue
-0-0-0---
52,47647,01741,34132,63137,29232,717
Revenue Growth
20.88%13.73%26.69%-12.50%13.98%23.79%
Cost of Revenue
45,09141,21538,84230,76924,86322,208
Gross Profit
7,3855,8022,4991,86212,42910,509
Selling, General & Admin
9,1948,7658,8108,7739,3195,362
Research & Development
573.69642.58694.43453.68--
Amortization of Goodwill & Intangibles
81.7283.1242.2137.6437.3430.24
Other Operating Expenses
170.07165.66195.81258.63155.54125.31
Operating Expenses
12,00811,71011,11810,53811,6295,878
Operating Income
-4,623-5,908-8,619-8,676800.054,632
Interest Expense
-5,609-5,425-5,086-3,764-2,015-832.82
Interest & Investment Income
799.91909.981,6901,053612.44141.09
Earnings From Equity Investments
20.93-4.11-42.5-3.53175.8204.81
Currency Exchange Gain (Loss)
308.02-134.24164.72-9-78.54-53.03
Other Non Operating Income (Expenses)
-553.962,1913,933-442.15-1,531756.47
EBT Excluding Unusual Items
-9,657-8,371-7,961-11,842-2,0364,848
Gain (Loss) on Sale of Investments
3,7698,030-1,24212.641,4721,846
Gain (Loss) on Sale of Assets
-11.29-5.43-22.86-3.75-79.8-209.58
Other Unusual Items
--404.11---
Pretax Income
-5,900-345.7-8,822-11,833-643.876,485
Income Tax Expense
1,2211,2283,836-2,883-708.61-213.18
Earnings From Continuing Operations
-7,120-1,573-12,657-8,95064.746,698
Earnings From Discontinued Operations
----1,447281.99
Net Income to Company
-7,120-1,573-12,657-8,9501,5126,980
Minority Interest in Earnings
3,1252,7366,2304,0731,214134.31
Net Income
-3,9951,163-6,427-4,8782,7257,114
Net Income to Common
-3,9951,163-6,427-4,8782,7257,114
Net Income Growth
-----61.69%172.19%
Shares Outstanding (Basic)
151616151515
Shares Outstanding (Diluted)
151616151515
Shares Change
-2.19%-1.56%2.86%5.42%-4.91%5.41%
EPS (Basic)
-258.6974.43-405.00-316.14186.19486.65
EPS (Diluted)
-258.6974.43-405.00-316.14185.86444.28
EPS Growth
-----58.17%148.20%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,9014,515-9,097-20,691-31,985-3,273
Free Cash Flow Per Share
123.07289.02-573.25-1341.02-2185.30-212.62
Gross Margin
14.07%12.34%6.04%5.71%33.33%32.12%
Operating Margin
-8.81%-12.57%-20.85%-26.59%2.15%14.16%
Profit Margin
-7.61%2.47%-15.55%-14.95%7.31%21.74%
Free Cash Flow Margin
3.62%9.60%-22.00%-63.41%-85.77%-10.00%
EBITDA
-158.77-1,576-4,521-4,9982,7456,304
EBITDA Margin
-0.30%-3.35%-10.94%-15.32%7.36%19.27%
D&A For EBITDA
4,4644,3334,0983,6791,9451,672
EBIT
-4,623-5,908-8,619-8,676800.054,632
EBIT Margin
-8.81%-12.57%-20.85%-26.59%2.15%14.16%
Advertising Expenses
-133.08121.57137.0771.9658.04